NCT04483947 - A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 6, 2020

Primary Completion Date

December 18, 2023

Study Completion Date

December 18, 2023

Conditions

Non-alcoholic Steatohepatitis (NASH)

Interventions

DRUG

AZD2693

Subcutaneous administration of AZD2693 multiple ascending doses in participants with NASH and who are carriers of the PNPLA3 148M risk allele(s).

OTHER

Placebo

Participants randomised to placebo will receive the corresponding dose volume of solution as participants receiving AZD2693 within the same cohort

Trial Locations (16)

17033

Research Site, Hershey

28557

Research Site, Morehead City

33014

Research Site, Hialeah

Research Site, Miami Lakes

33016

Research Site, Hialeah

33166

Research Site, Doral

43213

Research Site, Columbus

46202

Research Site, Indianapolis

75203

Research Site, Dallas

76012

Research Site, Arlington

78215

Research Site, San Antonio

78229

Research Site, San Antonio

91763

Research Site, Montclair

91911

Research Site, Chula Vista

91942

Research Site, La Mesa

92103

Research Site, San Diego